Article

Gregory J. Riely on MET Exon 14 Skipping Mutations in Lung Cancer

Author(s):

Gregory J. Riely

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of MET exon 14 skipping mutations in lung cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Related Content
Image of woman, with text.
July 14th 2025

The Evolution of Survivorship After a Lung Cancer Diagnosis

Ryan Scott
In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung cancer diagnosis to present day.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
July 10th 2025

FDA OKs New Test to Match Lung Cancer Patients With Targeted Therapies

Ryan Scott
The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of lung.
June 30th 2025

June Lung Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.
Sue McCarthy received diagnoses of breast cancer in 2001 and lung cancer in 2018. Catch up on all of Sue's blogs here!
June 26th 2025

Caring for Patients With Cancer Beyond Remission

Sue McCarthy
I entered remission from lung cancer 5.5 years ago, but faced a tough road readjusting, with ongoing physical, mental and emotional challenges.